Results 211 to 220 of about 219,659 (312)

A symposium update on the key perspectives in systemic sclerosis and systemic lupus erythematosus. [PDF]

J Transl Autoimmun
Renaudineau Y, Hedrich CM, Guery JC, Miyara M, Damoiseaux J, Mouthon L, Pugnet G, Faguer S, Delpuech A, Bellière J, Sailler L, Puissant B, Fusaro M.   +12 more
europepmc   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Bullous Systemic Lupus Erythematosus: Clinical Presentation in Two Asian Cases. [PDF]

Case Rep Med
Nguyen PTT, Nguyen TTP, Nguyen HV, Nguyen ATM, Pham NTU.   +4 more
europepmc   +1 more source

Impact of empiric potassium supplementation on mortality, sudden cardiac arrest and stroke in furosemide initiators

British Journal of Clinical Pharmacology, EarlyView.
Aim A prior non‐randomized study suggests that potassium supplementation may improve survival among furosemide initiators, and a randomized trial suggests that salt substitutes containing potassium might lower stroke risk. We conducted a retrospective cohort study using health‐care data to confirm or refute these associations among new users of ...
Thanh Phuong Pham Nguyen, Sean Hennessy, Colleen M. Brensinger, Warren B. Bilker, Laura M. Dember, Todd A. Miano, Tat‐Thang Vo, Allison W. Willis, Charles E. Leonard   +8 more
wiley   +1 more source

Moulage: "Lupus Erythematosus"

Dermatology Practical & Conceptual, 2011
openaire   +3 more sources

From Genes to Pathways: The Molecular Landscape of Systemic Lupus Erythematosus. [PDF]

Int J Mol Sci
Rashid R, Ramirez-Ortiz ZG.
europepmc   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

Persistent cutaneous lupus erythematosus: A pathway toward systemic disease? [PDF]

J Transl Autoimmun
Wang Q, Chen M, Jin H, Xiao J, Zhang Y.
europepmc   +1 more source

Lost and found in translation: the value of the human imiquimod model

British Journal of Clinical Pharmacology, EarlyView.
Topical imiquimod (IMQ), a Toll‐like receptor (TLR) 7 agonist, induces transient cutaneous inflammation and is widely used in preclinical research as a ‘psoriasis‐like’ mouse model. However, accumulating evidence indicates substantial divergence between IMQ‐driven biology and human plaque psoriasis pathogenesis.
Anouk C. Meijs, Juliette A. van den Noort, Salma Assil, Naomi B. Klarenbeek, Matthijs Moerland, Tessa Niemeyer‐van der Kolk, Robert Rissmann   +6 more
wiley   +1 more source

Plasmacytoid dendritic cells in systemic and cutaneous lupus erythematosus: an evolving understanding. [PDF]

Front Immunol
Werth VP, Rönnblom L, Wenzel J, Moseley MK, Gaiha-Rohrbach J, Reynolds TL, Barbey C, Grogan JL, Colonna M.   +8 more
europepmc   +1 more source